Tocilizumab (TCZ) treatment improves disease activity regardless of CCP status in rheumatoid arthritis

Primary tabs

NEWS
Tocilizumab (TCZ) treatment improves disease activity regardless of CCP status in rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic systemic immune-mediated inflammatory disease attacking synovial tissue in multiple joints. The diagnosis is based on the combination of clinical signs and symptoms of arthritis collectively with autoantibody profiling and measurement of the acute phase response. Not just diagnosis, but Autoantibodies may also play a beneficial role in predicting response to some treatments for Rheumatoid arthritis(RA).

A group of investigators conducted a study to evaluate initial response to tocilizumab (TCZ) by a change in physician and patient-reported outcomes and laboratory parameters in a real-world cohort of patients with RA. The data was examined by autoantibody status to discover whether patients with seronegative RA had improved response to TCZ when compared to their seropositive complements.

Data in the study was included from CORRONA RA registry. Patients were admitted if they were started on TCZ and had data from a follow-up visit 4–8 months after beginning, as well as having information on serologic status. Serologic status was defined by the presence of anti-cyclic citrullinated peptide (CCP) antibodies. Changes in disease activity measures from baseline to follow-up visit were estimated.

The results showed that both CCP-negative and -positive groups had statistically significant improvement in patient-reported measures, physician-reported measurements, and acute phase reactants after 4-8 months of treatment with TCZ. However, improvement magnitude did not differ significantly by CCP status.

The study provides a concrete conclusion about the efficacy of TCZ in improving all patient- and physician-reported measures of disease activity among RA patients. Also, the response to TCZ did not vary by CCP status.

Source:

Seminars in Arthritis and Rheumatism

Link to the source:

http://www.semarthritisrheumatism.com/article/S0049-0172(16)30370-5/fulltext?rss=yes

The original title of the article:

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Authors:

Laura C. Cappelli ; Judy Lynn Palmer, ; et al.

 

SearchTags: 
Therapy, Tocilizumab, Rheumatoid arthritis, Autoantibodies, RCT, Efficacy, Antibodies to cyclic citrulline peptide
Log in or register to post comments